Supplemental material
Current Medical Research and Opinion
Volume 39, 2023 - Issue 8
Diabetes
Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates
Signe Baattrup Reitzela Department of Economics, EY Denmark, Frederiksberg, Denmark
https://orcid.org/0000-0002-2839-4510
https://orcid.org/0000-0002-2839-4510, Mette Bøgelunda Department of Economics, EY Denmark, Frederiksberg, Denmarkhttps://orcid.org/0000-0003-0866-9414
https://orcid.org/0000-0003-0866-9414, Amaury Basseb Middle East & Africa, Novo Nordisk Region South East Europe, Zurich, Switzerlandhttps://orcid.org/0009-0006-2412-8799
https://orcid.org/0009-0006-2412-8799, Olga Barszczewskab Middle East & Africa, Novo Nordisk Region South East Europe, Zurich, Switzerlandhttps://orcid.org/0000-0002-5953-7414
https://orcid.org/0000-0002-5953-7414 & Hongye Renc Middle East & Africa, Novo Nordisk Region North West Europe, Copenhagen S, DenmarkCorrespondence[email protected]
https://orcid.org/0000-0003-0080-4765
https://orcid.org/0000-0003-0080-4765